

NUCOG PROTOCOLS

FUTURE COOPERATION

Programme:

13.00 – 13.30: Arrival and coffee

13.30 – 13.35: Welcome /introduction (Chairman Hans von der Maase, Professor and Head of department; Department of Oncology, Rigshospitalet, Copenhagen)

13.35 – 14.00: Feedback on questionnaire (sent out May 2012) (Helle Pappot; consultant, Department of Oncology, Rigshospitalet, Copenhagen)

14.00 – 14.15: VINSOR / *An Exploratory Phase I Study with Sorafenib in Addition to Vinflunine in Progressive Locally Advanced or Metastatic Transitional Cell Carcinoma of the Urothelial Tract* (Anders Ullén, consultant, Department of Oncology, Karolinska University Hospital, Stockholm)

14.15 – 14.45: *A randomized multicenter study of carboplatin/gemcitabine versus vinflunine/gemcitabine as first line treatment in patients with metastatic urothelial carcinoma not eligible for cisplatin based chemotherapy* (Karin Holmsten, consultant, Department of Oncology, Karolinska University Hospital, Stockholm)

14.45 – 15.00: *A randomized phase II study of Vinflunine versus Vinflunine/Pemetrexed as second-line treatment in patients with metastatic urothelial carcinoma prior treated with platinum* (Helle Pappot; consultant, Department of Oncology, Rigshospitalet, Copenhagen ; Mads Agerbæk, consultant, Department of Oncology, Aarhus University Hospital, Aarhus)

15.00 – 15.30: Coffee break

15.30 – 16.30: NUCOG organization

- *Communication*
- *Secretariat*
- *Participation in NUCOG protocols*

(Hans von der Maase, Professor and Head of department; Department of Oncology, Rigshospitalet, Copenhagen)

16.30 – 17.00: Break

17.00 – 17.45: Protocol proposals for new indications

17.45 – 18.00: Q & A / Next steps

18.00: Buffet